- Home
- NDMO vs CELC Comparison
NDMO vs CELC Comparison
Compare NDMO & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- CELC
- Stock Information
- Founded
- NDMO 2019
- CELC 2011
- Country
- NDMO United States
- CELC United States
- Employees
- NDMO N/A
- CELC N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- CELC Medical Specialities
- Sector
- NDMO Finance
- CELC Health Care
- Exchange
- NDMO Nasdaq
- CELC Nasdaq
- Market Cap
- NDMO 661.7M
- CELC 594.7M
- IPO Year
- NDMO N/A
- CELC 2017
- Fundamental
- Price
- NDMO $10.62
- CELC $12.66
- Analyst Decision
- NDMO
- CELC Strong Buy
- Analyst Count
- NDMO 0
- CELC 6
- Target Price
- NDMO N/A
- CELC $29.17
- AVG Volume (30 Days)
- NDMO 218.6K
- CELC 257.7K
- Earning Date
- NDMO 01-01-0001
- CELC 11-14-2024
- Dividend Yield
- NDMO 6.75%
- CELC N/A
- EPS Growth
- NDMO N/A
- CELC N/A
- EPS
- NDMO N/A
- CELC N/A
- Revenue
- NDMO N/A
- CELC N/A
- Revenue This Year
- NDMO N/A
- CELC N/A
- Revenue Next Year
- NDMO N/A
- CELC N/A
- P/E Ratio
- NDMO N/A
- CELC N/A
- Revenue Growth
- NDMO N/A
- CELC N/A
- 52 Week Low
- NDMO $8.99
- CELC $11.51
- 52 Week High
- NDMO $11.24
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- NDMO 37.09
- CELC 28.22
- Support Level
- NDMO $10.62
- CELC $15.33
- Resistance Level
- NDMO $10.77
- CELC $16.14
- Average True Range (ATR)
- NDMO 0.13
- CELC 0.97
- MACD
- NDMO 0.00
- CELC -0.28
- Stochastic Oscillator
- NDMO 15.28
- CELC 22.85
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.